Fig. 2.

RAR agonists induce SCX nuclear localization in human TSCs a–d. The effect was observed in a dose–response manner and EC₅₀ curves could be generated from a SCX nuclear localization algorithm looking at nuclear translocation and corresponding cell counts for different RAR agonists (tazarotene, CD1530, retinoic acid) and an antagonist (CD2665) e, f. Co-treatment with the RARγ antagonist CD2665 (1 μM) was able to induce a shift in the tazarotene EC₅₀ curve g. Phase-contrast images showing different cell morphologies between control and tazarotene-treated cells h, i. Western blot quantification of total SCX protein remaining unchanged following treatment with tazarotene j ATRA all-trans retinoic acid, DMSO dimethyl sulfoxide, hr hours, Scx scleraxis, Taz tazarotene